ACADIA Pharmaceuticals to Present at the Goldman Sachs 40th Annual Global Healthcare Conference

SAN DIEGO—(BUSINESS WIRE)—Jun. 4, 2019—ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical companyfocused on the development and commercialization of innovative medicinesthat address unmet medical needs in central nervous system disorders,today announced that it will present at the Goldman Sachs 40^thAnnual Global Healthcare Conference on Tuesday, June 11, 2019 at 1:20p.m. Pacific Time in Rancho Palos Verdes, California.

A live webcast of ACADIA’s presentation will be accessible on thecompany’s website, www.acadia-pharm.com,under the investors section and an archived recording will be availableon the website through July 11, 2019.

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company focused on the development andcommercialization of innovative medicines to address unmet medical needsin central nervous system disorders. ACADIA has developed andcommercialized the first and only medicine approved for the treatment ofhallucinations and delusions associated with Parkinson’s diseasepsychosis. ACADIA also has ongoing clinical development efforts inadditional areas with significant unmet need, including dementia-relatedpsychosis, schizophrenia inadequate response, schizophrenia-negativesymptoms, major depressive disorder, and Rett syndrome. This pressrelease and further information about ACADIA can be found at: www.acadia-pharm.com.

Source: ACADIA Pharmaceuticals Inc.

Investor Contact:

ACADIA Pharmaceuticals Inc.
MarkJohnson, CFA
(858) 261-2771
ir@acadia-pharm.com

Media Contact:

ACADIA Pharmaceuticals Inc.
MaurissaMessier
(858) 768-6068
media@acadia-pharm.com